Regulatory15 May 2026, 02:40 pm
Sai Life Sciences: Monitoring Agency Report for Q4 FY26
AI Summary
Sai Life Sciences Ltd has released the Monitoring Agency Report for the quarter and year ended March 31, 2026, as per Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report, issued by CRISIL Ratings Limited, monitors the utilization of IPO proceeds. The report indicates no deviations from the IPO's stated objectives. As of March 31, 2026, ₹345.88 million has been spent out of the ₹401.16 million allocated for issue expenses, with the remaining ₹55.28 million parked in fixed deposits and a public offer account.
Key Highlights
- CRISIL Ratings Limited is the Monitoring Agency for IPO proceeds.
- No deviations reported from the IPO's stated objectives.
- ₹345.88 million spent on issue expenses as of March 31, 2026.
- Remaining ₹55.28 million parked in fixed deposits and public offer account.
- Report submitted in accordance with SEBI guidelines.
Price Impact
More from SAILIFE